Reva Medical (ASX:RVA) said yesterday that the first Fantom bioresorbable scaffold was implanted in Italy.
The sirolimus-eluting device is made using a tyrosine-derived polymer that is visible under x-ray. Data from Reva’s Fantom II clinical trial found that the device resulted in a 4.2% rate of major adverse cardiac events after 12 months and 5.6% after 24 months.
Get the full story at our sister site, Drug Delivery Business News.
The post Reva implants first Fantom bioresorbable scaffold in Italy appeared first on MassDevice.